Keywords
How to Cite
Abstract
Minimal change disease is the main cause of nephrotic syndrome in children and a rare cause in adults, usually associated with secondary causes; predominantly haematological. This type of glomerulopathy is rare diagnosed synchronously in patients with solid tumors. We present the case of a 35-year-old patient with a recent diagnosis of rectal cancer who is admitted with a condition compatible with nephrotic syndrome, who is diagnosed with minimal change disease in the renal biopsy, with partial improvement in the condition after surgical management of neoplastic pathology. We consider that this case may be useful in the diagnostic approach and the management of patients with solid tumors of gastrointestinal origin with concomitant nephrotic syndrome.
References
Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol. el 7 de febrero de 2017;12(2):332–45.
Canetta PAA, Radhakrishnan J. The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Front Pediatr [Internet]. el 25 de septiembre de 2015 [citado el 1 de mayo de 2020];3. Disponible en: http://journal.frontiersin.org/Article/10.3389/fped.2015.00078/abstract
Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, et al. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis. Expert Opin Investig Drugs. el 2 de noviembre de 2018;27(11):839–79.
Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant. el 1 de agosto de 2003;18(90006):52vi–58.
Gonzalez-Fontal GR, Restrepo JG, Henao-Martinez AF. Minimal-change disease as a paraneoplastic syndrome in a patient with ovarian carcinoma. Clin Kidney J. el 1 de diciembre de 2011;4(6):427–9.
Monga D, Jhaveri KD. Chapter 6: Glomerular Diseases and Cancer. En: Onco-Nephrology Curriculum [Internet]. American Society of Nephrology; 2016. p. 1–9. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter6.pdf
Taniguchi K, Fujioka H, Torashima Y, Yamaguchi J, Izawa K, Kanematsu T. Rectal Cancer with Paraneoplastic Nephropathy: Association of Vascular Endothelial Growth Factor. Dig Surg. 2004;21(5–6):455–7.
Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, et al. Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol. abril de 2016;29(2):143–52.
Lien Y-HH, Lai L-W. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. febrero de 2011;7(2):85–95.
Cambier J-F, Ronco P. Onco-Nephrology: Glomerular Diseases with Cancer. Clin J Am Soc Nephrol. octubre de 2012;7(10):1701–12.
Bacchetta J, Juillard L, Cochat P, Droz J-P. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol. abril de 2009;70(1):39–58.
Yildiz H, Andreea SI, Hoton D, Cyr Yombi J. Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature. BMJ Case Rep. el 19 de diciembre de 2016;bcr2016217958.
Khow KSF, Yong ASM, Yong TY, Kuss BJ, Barbara JAJ, Li JYZ. Minimal change disease associated with newly diagnosed mantle cell lymphoma. Ren Fail. mayo de 2014;36(4):634–7.
Wągrowska-Danilewicz M, Danilewicz M. Nephrotic Syndrome and Neoplasia: Our expetience and review of the literature. el 11 de mayo de 2011;62(1):12–8.
Hogan J, Radhakrishnan J. The Treatment of Minimal Change Disease in Adults. J Am Soc Nephrol. mayo de 2013;24(5):702–11.
Fenton A, Smith SW, Hewins P. Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrol. diciembre de 2018;19(1):207.
Nicholas PD, Garrahy I. Adult minimal change disease with acute kidney injury: a case report and literature review. J Community Hosp Intern Med Perspect. el 2 de noviembre de 2019;9(6):507–10.
Plaisier E, Ronco P. Screening for Cancer in Patients with Glomerular Diseases. Clin J Am Soc Nephrol. el 4 de febrero de 2020;CJN.09000819.
Ahn W, Bomback AS. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. Am J Kidney Dis. junio de 2020;75(6):955–64.
Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. febrero de 2019;95(2):281–95.
Korbet SM, Whittier WL. Management of Adult Minimal Change Disease. Clin J Am Soc Nephrol. el 7 de junio de 2019;14(6):911–3.
Pinto H, Oliveira N, Costa F, Alves R. Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab. BMJ Case Rep. el 5 de febrero de 2018;bcr-2017-223407.
Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol. el 7 de febrero de 2020;15(2):209–18.
Lin R, McDonald G, Jolly T, Batten A, Chacko B. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep. abril de 2020;5(4):435–47.
Kelddal S, Nykjær KM, Gregersen JW, Birn H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol. diciembre de 2019;20(1):139.
Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. enero de 2017;32(1):157–64.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Revista Colombiana de Nefrología